Analyst picks & changes

BioChem Pharma Inc.

(BCHXF)

UBS Securities analyst David Crossen initiated coverage with a "buy" and a 12-18 month price target of

Read the full 214 word article

How to gain access

Continue reading with a
two-week free trial.